8-K 1 oxyb-8k_121109.htm OXYGEN BIOTHERAPEUTICS 8K FOR 12/11/2009 Oxygen Biotherapeutics, Inc. 8K for Period Ended 12/11/2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

Date of Report (Date of earliest event reported): December 11, 2009

OXYGEN BIOTHERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

2-31909
(Commission File No.)

Delaware 26-2593535
(State or Other Jurisdiction of
Incorporation or Organization)		 (IRS Employer Identification No.)

2530 Meridian Parkway, 3rd Floor, Durham, North Carolina 27713
(Address of principal executive offices)

(919) 806-4414
(Registrant’s telephone number)

Not applicable
(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[  ]    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]    Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

[  ]    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 5.02(d) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

The board of directors of Oxygen Biotherapeutics, Inc., adopted resolutions effective December 11, 2009, that:

  • Increase the number of persons comprising the board of directors to nine persons, as permitted by the terms of our bylaws; and
• Electing LTG Ronald R. Blanck (ret.) as a director to fill the vacancy on the board of directors thereby created.

The new director was not elected pursuant to any arrangement or understanding between him and any other person. Further, the new director was not involved in any transaction with us during the period beginning May 1, 2008, to December 11, 2009, and no transaction with him is currently proposed, outside of his service as a director. The new director will participate in the compensation arrangement established by us from time to time for non-employee directors, including the arrangement currently in place.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OXYGEN BIOTHERAPEUTICS, INC.

Date: December 11, 2009   By:   /s/ Chris J. Stern  
    Chris J. Stern, Chief Executive Officer  

2